1. Home
  2. DYN
  3. DYN News

Latest Dyne Therapeutics Inc. (DYN) News on July 9, 2025

DYN

MT Newswires

13 days ago

JonesTrading Initiates Coverage on Dyne Therapeutics With Buy Rating, $30 Price Target

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101
DYN

Insider Monkey

15 days ago

Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101

DYN

MT Newswires

15 days ago

Bernstein Initiates Dyne Therapeutics at Market Perform With $13 Price Target

Dyne at ‘attractive entry point’ following pullback, says Chardan
DYN

TipRanks

21 days ago

Dyne at ‘attractive entry point’ following pullback, says Chardan

DYN

MT Newswires

22 days ago

Dyne Therapeutics Granted Breakthrough Status for DYNE-101 to Treat Myotonic Dystrophy

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
DYN

GlobeNewswire

22 days ago

Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET
DYN

GlobeNewswire

23 days ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress
DYN

GlobeNewswire

a month ago

Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress

DYN

MT Newswires

a month ago

Oppenheimer Adjusts Dyne Therapeutics Price Target to $34 From $60, Maintains Outperform Rating

This week in Trumponomics: Too bad TACO isn’t true
DYN

Yahoo Finance

a month ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right
DYN

The Guardian

a month ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF
DYN

Yahoo Finance Video

a month ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Ford recalls more than 29,000 vehicles in the US, NHTSA says
DYN

Reuters

a month ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states
DYN

USA TODAY

a month ago

Smoke from Canadian wildfires worsens air quality in Dakotas, Midwestern states

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching
DYN

Simply Wall St.

a month ago

Here's Why We Think HBT Financial (NASDAQ:HBT) Is Well Worth Watching

Saturday Sessions: OK Go performs "Love"
DYN

CBS News Videos

a month ago

Saturday Sessions: OK Go performs "Love"

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate
DYN

Simply Wall St.

a month ago

We're Not Very Worried About Black Swan Graphene's (CVE:SWAN) Cash Burn Rate

DYN

MT Newswires

2 months ago

RBC Cuts Price Target on Dyne Therapeutics to $30 From $36, Keeps Outperform, Speculative Risk

DYN

MT Newswires

2 months ago

Dyne Therapeutics Q1 Loss Widens

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
DYN

GlobeNewswire

2 months ago

Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy
DYN

Pharmaceutical Technology

2 months ago

EC grants orphan drug designation to Dyne Therapeutics’ DMD therapy

DYN

MT Newswires

3 months ago

Dyne Therapeutics Gets EU Orphan Drug Status for Duchenne Treatment

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
DYN

Investor's Business Daily

3 months ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DYN

GlobeNewswire

3 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m
DYN

Simply Wall St.

3 months ago

Insider Purchases Worth US$1.06m See Losses As Dyne Therapeutics Market Value Drops To US$770m

DYN

MT Newswires

3 months ago

RBC Cuts Price Target on Dyne Therapeutics to $36 From $41, Keeps Outperform, Speculative Risk

Biotech stocks slide as Marks resignation seen being negative for sector
DYN

TipRanks

3 months ago

Biotech stocks slide as Marks resignation seen being negative for sector

DYN

MT Newswires

4 months ago

Sector Update: Health Care Stocks Steady Premarket Friday

DYN

MT Newswires

4 months ago

Dyne Therapeutics Names Erick Lucera as CFO

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer
DYN

GlobeNewswire

4 months ago

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
DYN

GlobeNewswire

4 months ago

Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer

DYN

MT Newswires

4 months ago

Sector Update: Health Care Stocks Decline Premarket Monday

DYN

MT Newswires

4 months ago

Dyne Therapeutics Says Trial of Potential Duchenne Muscular Dystrophy Drug Shows 'Meaningful' Results

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months
DYN

GlobeNewswire

4 months ago

Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
DYN

Benzinga

4 months ago

Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks

BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
DYN

GuruFocus.com

4 months ago

BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating

DYN

MT Newswires

4 months ago

BMO Capital Initiates Dyne Therapeutics Inc at Outperform With $50 Price Target

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum
DYN

GlobeNewswire

4 months ago

Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum

DYN

MT Newswires

4 months ago

RBC Cuts Price Target on Dyne Therapeutics to $41 From $45, Keeps Outperform, Speculative Risk

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?
DYN

Simply Wall St.

4 months ago

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Deliver On Growth Plans?

DYN

MT Newswires

4 months ago

Dyne Therapeutics Q4 Net Loss Narrows; Shares Rise

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
DYN

GlobeNewswire

4 months ago

Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference
DYN

GlobeNewswire

5 months ago

Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)
DYN

Zacks

5 months ago

After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN)

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now
DYN

Insider Monkey

5 months ago

Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
DYN

GlobeNewswire

5 months ago

Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
DYN

Zacks

5 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
DYN

Zacks

5 months ago

5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround
DYN

Zacks

5 months ago

Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround

DYN

MT Newswires

6 months ago

Dyne Therapeutics Says US FDA Grants Fast Track tag to Neuromuscular Disease Therapy

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
DYN

GlobeNewswire

6 months ago

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

DYN

MT Newswires

6 months ago

Dyne Therapeutics' Muscle Dystrophy Treatment Demonstrates DMPK Reduction, Splicing Correction; Shares Fall

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
DYN

GlobeNewswire

6 months ago

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
DYN

GlobeNewswire

6 months ago

Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
DYN

GlobeNewswire

6 months ago

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET

DYN

MT Newswires

7 months ago

Baird Initiates Dyne Therapeutics at Outperform With $46 Price Target

DYN

MT Newswires

7 months ago

RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target

Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
DYN

Insider Monkey

8 months ago

Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts

DYN

MT Newswires

8 months ago

Dyne Therapeutics' Q3 Loss Narrows

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
DYN

GlobeNewswire

8 months ago

Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

DYN

MT Newswires

9 months ago

JPMorgan Downgrades Dyne Therapeutics to Neutral From Overweight, Adjusts Price Target to $35 From $43

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
DYN

GlobeNewswire

9 months ago

Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
DYN

Insider Monkey

9 months ago

Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
DYN

GlobeNewswire

10 months ago

Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference

DYN

MT Newswires

10 months ago

Dyne Therapeutics Insider Sold Shares Worth $308,864, According to a Recent SEC Filing

CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares
DYN

Simply Wall St.

10 months ago

CEO, President & Director of Dyne Therapeutics John Cox Buys 640% More Shares

Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More
DYN

Zacks

10 months ago

Biotech Stock Roundup: NVAX Vaccine Approval, ALNY, ATHA Stock Dive on Updates & More

DYN

MT Newswires

10 months ago

Dyne Therapeutics Insider Bought Shares Worth $1,057,216, According to a Recent SEC Filing

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
DYN

Zacks

10 months ago

Dyne Reports Mixed Data From DMD Study, Key Executives Step Down

High-dose Spinraza meets study goal; Top Dyne executives exit
DYN

BioPharma Dive

10 months ago

High-dose Spinraza meets study goal; Top Dyne executives exit

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
DYN

Investor's Business Daily

10 months ago

Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
DYN

Benzinga

10 months ago

Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy

DYN

MT Newswires

10 months ago

Dyne Therapeutics Duchenne Muscular Dystrophy Drug Study Shows Improvements -- Shares Tumble

Dyne Therapeutics Announces Key Leadership Appointments
DYN

GlobeNewswire

10 months ago

Dyne Therapeutics Announces Key Leadership Appointments

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
DYN

GlobeNewswire

10 months ago

Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
DYN

GlobeNewswire

10 months ago

Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

DYN

MT Newswires

a year ago

Chardan Adjusts Price Target on Dyne Therapeutics to $50 From $42, Maintains Buy Rating

DYN

MT Newswires

a year ago

Dyne Therapeutics Q2 Loss Narrows

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why
DYN

Zacks

a year ago

Recent Price Trend in Dyne Therapeutics (DYN) is Your Friend, Here's Why

What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
DYN

Zacks

a year ago

What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?

Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
DYN

Zacks

a year ago

Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why

DYN

MT Newswires

a year ago

JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating

DYN

MT Newswires

a year ago

Dyne Therapeutics Insider Sold Shares Worth $1,401,902, According to a Recent SEC Filing

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease

DYN

MT Newswires

a year ago

Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress
DYN

GlobeNewswire

a year ago

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

DYN

MT Newswires

a year ago

Dyne Therapeutics Insider Sold Shares Worth $2,583,782, According to a Recent SEC Filing

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities
DYN

GlobeNewswire

a year ago

$6.6 Billion Digital X-ray Market, 2024-2029: Development of AI-based Digital X-Ray Systems Present Business Opportunities

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)
DYN

Motley Fool

a year ago

2 Reasons to Buy Rivian Stock (and 1 Big Reason to Sell)

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans
DYN

CNW Group

a year ago

DFR Gold Inc. Announces Amendment of WUO Land Option and Insider Loans

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike
DYN

Investor's Business Daily

a year ago

Walmart Stock Climbs After Dow Jones Giant Receives Upgrade, Major Price Target Hike

EPCOR and HAWSCo Enter Ownership Transfer Agreement
DYN

CNW Group

a year ago

EPCOR and HAWSCo Enter Ownership Transfer Agreement

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate
DYN

GlobeNewswire

a year ago

Video on Demand (VoD) Market Report 2024-2034: Netflix, Amazon, Google and Hulu Dominate

Southwest Airlines stock pops on report of Elliott's $2B stake
DYN

Yahoo Finance Video

a year ago

Southwest Airlines stock pops on report of Elliott's $2B stake

DYN

Business Wire

a year ago

Form 8.3 - Virgin Money UK plc

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
DYN

GOBankingRates

a year ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
DYN

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Share on Social Networks: